InvestorsHub Logo
Followers 2433
Posts 91301
Boards Moderated 7
Alias Born 09/12/2003

Re: Valuetrader post# 15771

Friday, 01/10/2020 11:36:35 AM

Friday, January 10, 2020 11:36:35 AM

Post# of 27415
$ASRT 1.08 a bullish rating on it's equity summary score. PENDING NEWS. This is a great time to get in on this one.

Assertio Therapeutics Announces Sale of Gralise® for Total Transaction Value of $127.5 Million
GlobeNewswire GlobeNewswire•December 12, 2019
LAKE FOREST, Ill., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio”) (ASRT), today announced it has entered into an agreement with Alvogen, a global privately held pharmaceutical company, under which Alvogen will acquire and assume all responsibilities associated with the product Gralise® (gabapentin). The agreement is expected to close in early January 2020, subject to regulatory approval.

Under the terms of the agreement, Alvogen will pay Assertio a total value of $127.5 million. This includes $75 million in cash upon closing and the balance payable in the form of a royalty on the first $70 million in Gralise® net sales. Both companies expect the majority of the royalties to be paid in the first calendar year.

https://finance.yahoo.com/news/assertio-therapeutics-announces-sale-gralise-125010016.html

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.